We are live on ! Find out more

SciSparc

SPRC

Market cap $3.13M

5.39 USD

+0.38

7.58%

At close Updated Sep 24, 4:00 PM EDT

Pre-market

After hours

5.39

0.00

0%

1 day

7.58%

5 days

20.31%

1 month

-19.07%

3 months

-8.18%

6 months

23.91%

Year to date

-57.22%

1 year

-84.36%

5 years

-99.98%

10 years

-99.98%

About: SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two operating reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.

Employees: 3

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 95.8%

Negative 4.2%

SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations

The U.S. patent applications cover proprietary combinations of NeuroThera's PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression and PTSD as well as substance use disorders

SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations

SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

This strategic engagement is designed to strengthen NeuroThera's U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public ‑ health importance of advancing new treatment options for adult Tourette Syndrome TEL AVIV, Israel – TheNewswire - September 2, 2026 - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, today announced that it is pursuing U.S. Food and Drug Administration (“FDA”) Orphan Drug Designation covering SCI-110, its drug candidate for the treatment adults with Tourette Syndrome (“TS”), a rare condition that may qualify for Orphan Drug Designation.

SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

This strategic engagement is designed to strengthen NeuroThera's U.S. market position, visibility among key U.S. federal stakeholders, reinforce the clinical and public ‑ health importance of advancing new treatment options for adult Tourette Syndrome TEL AVIV, Israel – TheNewswire - September 2, 2026 - SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, today announced that it is pursuing U.S. Food and Drug Administration (“FDA”) Orphan Drug Designation covering SCI-110, its drug candidate for the treatment adults with Tourette Syndrome (“TS”), a rare condition that may qualify for Orphan Drug Designation.

SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies

SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, continued advancement in participant enrollment for the clinical trial assessing NeuroThera's innovative SCI-210 treatment for symptoms associated with autism spectrum disorder (“ASD”).

SciSparc: Subsidiary NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

Toronto, Ontario, August 31, 2026 – TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage pharmaceutical company and a subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announced continued advancement in participant enrollment for its clinical trial assessing its innovative SCI-210 treatment for symptoms associated with autism spectrum disorder (“ ASD ”). The clinical trial, conducted at Soroka Medical Center in Israel, is a double-blind, randomized, placebo-controlled study evaluating the safety and efficacy of SCI-210 in children diagnosed with ASD. To date, 26 children have been enrolled, marking strong progress toward the planned total of 60 children between the ages of five and 18, each of whom will receive treatment over a 20-week period.

NeuroThera Labs Achieves Significant Enrollment Momentum in SCI‑210 Autism Clinical Trial

Neurothera Labs Inc. Announces Share Consolidation

Toronto, Ontario – August 28, 2026 – – TheNewswire - NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that, in accordance with special resolution of shareholders passed on January 8, 2026 (the “ Consolidation Resolution ”), the Company will be implementing a consolidation (the “ Consolidation ”) of the outstanding common shares in the capital of the Company (the “ Common Shares ”) on the basis of one new Common Share (each, a “ Post-Consolidation Share ”) for every fourteen (14) currently outstanding Common Shares (the " Consolidation Ratio "). The Company believes that the increase to the trading price of the Common Shares from effecting the consolidation could potentially and principally broaden the pool of investors that may consider investing or be able to invest in the Company as well as enable the Company to satisfy certain minimum trading price requirements of U.S. and other stock exchanges for a potential listing of the Common Shares.

Neurothera Labs Inc. Announces Share Consolidation

NeuroThera Labs Engages Dr. Reuter Investor Relations

Toronto, Ontario – August 27, 2026 – TheNewswire - NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that it has engaged Dr. Reuter Investor Relations (" Dr. Reuter ") to provide investor awareness and communications services across Germany and the broader European capital markets, effective September 1, 2026. Dr. Reuter is a recognized European investor relations and financial communications firm with an established network of institutional investors, retail shareholders, and financial media throughout the DACH region and the European Union. The engagement is intended to enhance the Company's visibility among European investors, support market education regarding its clinical research strategy, and strengthen shareholder communications. Dr. Reuter's business address is Tower 185, Friedrich-Ebert-Anlage 35-37, 60327 Frankfurt, Germany, and the firm may be contacted at [email protected] .

NeuroThera Labs Engages Dr. Reuter Investor Relations

SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board

The addition of leading AI researcher further strengthens SciSparc's scientific and technical foundation as the Company advances its strategic focus on the Agentic AI market

SciSparc Advances Agentic AI Strategy with Addition of Internationally Recognized AI Expert Prof. Carmel Domshlak to Scientific Advisory Board

SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

U.S. publication of a patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration, and provides guidance addressing clinical development considerations for psychedelic drugs, including MDMA

SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc's Stake Valued at Approximately C$30 Million

SciSparc Invests C$2.7 million and holds approximately 44.6% of NeuroThera's issued and outstanding common shares following the financing

SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc's Stake Valued at Approximately C$30 Million

See News Rankings

Price charts implemented using Lightweight Charts™